Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Phase 2 Completed 28 enrolled NCIC Clinical Trials Group National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients who have metastatic or recurrent prostate cancer that has not responded to previous hormone therapy.

Timeline

Start: 2004-08-10
Primary completion: 2006-09-28
Completion: 2011-01-18

Publications

Results Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol. 2008 Apr;19(4):746-51. doi: 10.1093/annonc/mdm554. Epub 2007 Dec 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	400 mg	Oral

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications